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Available online 22 April 2016This randomizedwithin-subject, double blind study aimed to compare the effects of a single dose of two different
antipsychotics (haloperidol and aripiprazole) on cortisol, interleukin (IL)-6 and hippocampal regional Cerebral
Blood Flow (rCBF) in the same 17 healthy male individuals. Subjects received a single dose of haloperidol
(3mg), aripiprazole (10mg) and placebo, in a randomized order on three study appointments.Wemeasured sal-
ivary cortisol levels at multiple time points, IL-6 levels from plasma samples, and resting cerebral blood ﬂow
(rCBF), using a pulsed continuous arterial spin labeling (pCASL) sequence (1.5T). We found signiﬁcantly lower
cortisol levels in the haloperidol condition (F(2,32) = 5.78, p = 0.007), than in either placebo (p = 0.013;
CI= 0.45, 0.406) or aripiprazole (p=0.037; CI=−0.520,−0.014). Interleukin-6 levels were also lower follow-
ing haloperidol (F(2,22)= 4.19, p = 0.048) in comparison with placebo (p= 0.02; CI = 0.14, 1.8), but not with
aripiprazole. Finally, we found a greater rCBF in the right (peak voxel: T = 6.47, p b 0.0001) and left (peak voxel
T= 5.17, p b 0.01) hippocampus following haloperidol comparedwith placebo, and at trend level also in the left
hippocampus following aripiprazole compared with placebo (T = 4.07, p = 0.057). These differences in hippo-
campal rCBF after both antipsychotics were no longer evident (haloperidol) or present at trend level
(aripiprazole), after controlling for cortisol and IL-6 levels. Our ﬁndings suggest that haloperidol can directly reg-
ulate the hypothalamic-pituitary-adrenal (HPA) axis and immune system through a pharmacological action via
D2 receptor antagonism. Finally, our data suggest that the increased hippocampal rCBF is a manifestation of the
reduction in IL-6 and cortisol which follows the administration of haloperidol.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Over the past few decades, an increasing number of studies have
reported a hyper-activation of the hypothalamic-pituitary-adrenal
(HPA) axis and of the immune system in patients with psychosis.
These two biological systems are responsible for the main brain and
behavioural changes occurring in response to stress, as well as for our
defence against external pathogens. Of note, both the HPA axis and
the immune system have been shown to contribute to some of the ab-
normalities in brain structure and function found at psychosis onsetl Neuroscience Institute, Room
cience, King's College London,
y).
. This is an open access article under(Borges et al., 2013; Mondelli et al., 2011; Zajkowska and Mondelli,
2014), and have been proposed as optimal targets for developing new
treatments for psychosis. However, it remains unclear if and how HPA
axis and the immune system are affected by antipsychotic medications,
and indeed if the effect of antipsychotics on the brain is partly mediated
by the modulation of these biological systems.
Elevated levels of cortisol, the ﬁnal hormone produced by the
activation of the HPA axis, and of inﬂammatory markers, such interleu-
kin (IL)-6, have been consistently shown in subjects with psychosis
(even prior to treatment) and in non-psychotic at-risk individuals, indi-
cating that the activation of these biological systems partly predate the
onset of psychosis (Aiello et al., 2012; Borges et al., 2013). A dysregula-
tion of these systemsmay result from prolonged exposure to psychoso-
cial stress, and represent the biological mediator underpinning the
relationship between stressful events (for example in childhood) and
the development of psychotic symptoms (Walker and Diforio, 1997).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ity and inﬂammation lead to the onset of psychotic symptoms remain
unknown, multiple pathways modulating monoaminergic systems
and synaptic plasticity have been proposed. Interestingly, both cortisol
and IL-6 directly interact with the hippocampus, a brain region consis-
tently reported as altered in structure, function and activity in psychosis
(Tamminga et al., 2010), suggesting that stress hormones and pro-
inﬂammatory markers play a key role in mediating some of the key
physiological brain changes observed in this condition. Indeed, elevated
levels of both cortisol and IL-6 have been related with smaller hippo-
campal volumes in healthy subjects, as well as in subjects with ﬁrst
episode psychosis (Marsland et al., 2008; Mondelli et al., 2011).
We have previously reported that some of the structural and func-
tional brain changes observed in psychosis are related to antipsychotic
treatment (Dazzan et al., 2005; Goozee et al., 2016; Navari and
Dazzan, 2009), and that the mechanisms underpinning these changes
might partly depend on alterations in resting cerebral blood ﬂow
(rCBF) (Goozee et al., 2014; Handley et al., 2013). In particular, in a
previous study in healthy volunteers, we showed that a single dose of
either haloperidol or aripiprazole affects rCBF in the same brain regions
which have been reported as structurally and functionally altered in
psychosis (Handley et al., 2013). However, the mechanisms through
which antipsychotic treatment affects rCBF remain unclear. Only very
few human studies have linked cerebral perfusion and cortisol levels,
with most data coming from animal studies. Interestingly, increased
CBF in hippocampus (and to a lesser degree in the prefrontal cortex)
has been described in adrenalectomized rats (Endo et al., 1994), while
reduced hippocampal rCBF has been reported after 12weeks of cortico-
sterone administration (Endo et al., 1997) or a similar period of stress
exposure in rats (Endo et al., 1999). Similarly, studies in humansmostly
report an inverse correlation between cortisol levels and cerebral
perfusion in the medial temporal lobe and anterior cingulate cortex
(Bonne et al., 2003; Hodkinson et al., 2014). Furthermore, the inﬂam-
matory cytokine IL-6 has been reported as a potent vasoconstrictor
(Tarkowski et al., 1995) and antibodies against IL-6 attenuate post-
hemorrhagic vasospasm (Bowman et al., 2004), possibly leading to a de-
crease in cerebral perfusion.
Evidence from our and other groups suggests that the levels of both
cortisol and IL-6 are affected by antipsychoticmedications, which possi-
bly re-establish ‘normal’ levels of these biomarkers and their regulatory
processes (Miller et al., 2011; Mondelli et al., 2010a). However, it
remains unclear whether this reﬂects a direct effect of these drugs on
the stress response system, or rather an indirect effect of the ameliora-
tion of psychotic symptoms induced by these drugs. Furthermore, it is
yet to be established whether antipsychotics with different pharmaco-
logical proﬁles affect these stress responsemarkers, and any potentially
associated brain change, differently.
Both ﬁrst (FGA) and second (SGA) generation antipsychotics have
been associatedwith cortisol changes in patients with psychosis, but in-
creasing evidence suggests that SGAs reduce cortisol to a greater extent
than FGAs (Jakovljevic et al., 2007; Popovic et al., 2007; Tanaka et al.,
2008; Zhang et al., 2005). Most direct comparisons of the effects of
FGAs and SGAs on stress markers have been conducted in patient
populations,with only one study conducted in a small sample of healthy
volunteers (Cohrs et al., 2006). This study demonstrated no effect of the
dopaminergic antagonist haloperidol on cortisol levels, and a reduction
on cortisol levels induced by SGA antipsychotics like quetiapine and
risperidone. The effect of SGAs on cortisol has been suggested to reﬂect
differences in afﬁnity and occupancy at the D2 and 5-HT receptor sub-
types (Meltzer, 1989).
Data on the effects of antipsychotics on IL-6 appear less consistent
(Baumeister et al., 2016). For example, in patients, FGAs and SGAs
have been found to increase, reduce or have no effect on IL-6 levels
(Maes et al., 1995; Tourjman et al., 2013; Zhang et al., 2005). Two recent
meta-analyses also reported conﬂicting results, indicating no signiﬁcant
effect of antipsychotic treatment on IL-6 (Tourjman et al., 2013) in onestudy, and a reduction of IL-6 after antipsychotic treatment in another
(Miller et al., 2011). In one in vitro investigation in healthy females,
IL-6 levels remained unchanged after both ﬁrst and second generation
antipsychotics (Himmerich et al., 2011). However, to the best of our
knowledge, the effects of FGA or SGAs on IL-6 in healthy volunteers
(in vivo) havenever been investigated. Furthermore, no evidence exists,
from either patients or healthy individuals, on the effects of a “third”
generation antipsychotic such as aripiprazole on cortisol or IL-6.
Given that antipsychotics directly affect cortisol and IL-6, and that
there is an association between these markers and cerebral blood
ﬂow, it is possible that the effect of antipsychotics on brain structure
and blood ﬂow is partly mediated by these biomarkers. Understanding
the differential effects of FGAs and SGAs will help clarify whether the
level of antagonism at D2, or other neurotransmitter receptors, such
as the serotonin, are important in regulating cortisol and IL-6 levels,
and whether these biomarkers mediate the drug-induced changes
evident in hippocampal rCBF.
This study compared the effects of two antipsychotics with very
different mechanisms of action: haloperidol, a strong D2 receptor
antagonist with comparatively lower afﬁnity for other receptors, such
as serotonin 5-HT2 (Meltzer, 1989), and aripiprazole, a partial D2 and
5HT1A receptor agonist with a lower afﬁnity for the serotonin 5-HT2A
than for the dopamine D2 receptor subtype (Mamo et al., 2007). We
compared the effects of a single dose of these two drugs on cortisol,
IL-6 and hippocampal rCBF in the same healthy individuals in compari-
son with placebo. This is the ﬁrst investigation of aripiprazole and
haloperidol (in vivo) effects on cortisol and IL-6. Moreover, it is the only
exploration of the effects of different antipsychotics on cortisol, IL-6 and
hippocampal perfusion in the same individuals. Amongst the various
pro-inﬂammatory cytokines which have been reported increased in psy-
chosis, we focussed in particular on IL-6 as this remains the main pro-
inﬂammatory cytokine which has been reported as elevated in patients
with psychosis, and as being linked to activation of the HPA axis. We
hypothesised that i) aripiprazole but not haloperidol would reduce corti-
sol; ii) both antipsychotics would reduce IL-6 levels and iii) reductions in
these biomarkers would account for some of the rCBF change evident in
the hippocampus following administration of these antipsychotics.
2. Methods
Seventeen healthy right-handed English speaking Caucasian males,
aged 18 to 32 (mean 22 years, SD 4.1) provided salivary cortisol samples
across the day and underwent a brain scan for the investigation of
resting blood ﬂow (rCBF). Twelve of them also provided blood samples
for the measurement of IL-6 levels. Mean body mass index was within
the normal range (mean 23.5, SD 3.7). Participants were non-smoking,
university students with no recent or current drug or medication use
and had no exposure to psychotropic medication, or history of personal
or familial psychiatric diagnosis. The studywas approved by theHuman
Research Ethics Committee of the Institute of Psychiatry, London, and
conducted in compliance with the Declaration of Helsinki. Written in-
formed consent was obtained from all participants after the nature of
the experimental procedures was explained to them.
Subjects received a single dose of haloperidol (3 mg), aripiprazole
(10 mg) and placebo, in a randomized order on three study appoint-
ments. A fully counterbalanced, randomized within-subject, double
blinded cross-over design was used, ensuring neither participant or re-
searcher were aware of the intervention administered on each appoint-
ment. Compounds were administered in identical capsules. Fourteen
days minimum separated each study appointment to allow for drug
washout. No alcohol or medications were used for 24 h, or caffeine for
6 h, prior to scanning.
Clinical side effects, measured using the Barnes Akathisia scale
(Barnes, 1989), the Simpson Angus scale (Simpson and Angus, 1970),
and the Abnormal Involuntary Movement Scale (AIMS: National
Institute of Mental Health), were evaluated 3 hours post intervention.
Fig. 1. Raw mean (with standard error bars) cortisol levels at individual time points:
baseline (pre intervention; 10:20 am), 1.45 hours post intervention (12.15) and
3.10 hours post intervention (13:40) after placebo (PLA), haloperidol (HAL) and
aripiprazole (ARI) administration.
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than placebo (χ2 = 7.3, p b 0.05). There were no signiﬁcant differences
across intervention in tardive dyskinesia (χ 2 = 2.0, n.s.), akathisia (all
participants had a negative score), systolic (F(2,32) = 2.16, not
signiﬁcant) or diastolic (F(2,32)= 0.15, not signiﬁcant) blood pressure.
2.1. Salivary cortisol and interleukin (IL)-6 assessment
Using salivary cortisol salivettes (Sarstedt, Leicester, UK) subjects
chewed on a cotton roll for 2 min per sample under observation, at
three time points including baseline (pre-intervention, morning),
1.45 h (post intervention, early afternoon), and 3.10 h (post interven-
tion mid-afternoon). The last sample was acquired 20 min prior to the
brain scan. Salivettes were frozen at−20 °C. After thawing, they were
centrifuged at 3500 rpm for 10 min, which resulted in a clear superna-
tant of low viscosity. Saliva cortisol concentrations were determined
using the “Immulite”—Siemens Immunoassay analyzer (www.
diagnostics.siemens.com). The plasma cortisol assay of the analyzer
was suitably modiﬁed and then validated for these measurements. A
set of 10 cortisol standards in saline were used in each assay to plot a
calibration graph. This was highly reproducible with slope of
(mean ± SEM) 0.197 ± 0.004. The method had analytical sensitivity
of 0.2 nmol/l and inter/intra assay precision (% CV) of b10% (cortisol
concentration range 5 to 25 nmol/l). All samples from the same subject
were analyzed in the same run.
For IL-6, one 4ml EDTA tube was collected 3.20 hours post interven-
tion (10 min prior to the rCBFmeasurement). Samples were stored in a
refrigerator (4°C) until the end of the testing day. Samples were later
(approximately 3.10 h after sample acquisition) centrifuged at
1600 rpm for 10 min to allow for serum extraction which was then fro-
zen at−80 °C. On study completion, plasma samples were unblinded
and outsourced to the Department of Clinical Biochemistry, King's
College Hospital London. Quantitative sandwich enzyme linked immu-
noassay (ELISA) analysis technique was conducted using a Quantikine
IL-6 ELISA kit distributed by R & D Systems (Abingdon).
2.2. Resting blood ﬂow (rCBF) acquisition
Participants underwent a 6 minute resting scan with eyes open and
images were acquired in a General Electric Signa HDX 1.5 tesla scanner
at the Centre for Neuroimaging Sciences, Institute of Psychiatry. rCBF
measurements were made using a pulsed-continuous arterial spin
labeling technique (see Handley et al., 2013 for full imaging technique,
acquisition and image pre-processing details). Two additional structur-
al, high spatial resolution images were acquired for co-registration and
normalisation, including a T2 weighted fast spin echo and ﬂuid-
attenuated inversion-recovery fast spin echo (FLAIR FSE) scan to ex-
clude the presence of any brain pathology.
2.3. Data analysis
Investigation of the cortisol and IL-6 data was conducted using the
Statistical Package for Social Sciences, Version 15.0 (SPSS Inc.). Extreme
outliers were investigated from variables for which normality assump-
tions (examined with the Shapiro-Wilk test) were violated and natural
logarithm was applied where normality was violated, but no extreme
outliers were identiﬁed. The Area Under the Curve (AUC) for cortisol
levels across the three time points was calculated based on the trape-
zoid formula (Pruessner et al., 2003). We ﬁrst explored the effects of in-
tervention on cortisol AUC and IL-6 levels using a repeated measures
analysis of variance (ANOVA), including intervention as the within-
subjects factor, followed by Bonferroni corrected post-hoc comparisons.
Building on our previously published work demonstrating a signiﬁ-
cant increase in hippocampal rCBF after haloperidol and aripiprazole
relative to placebo (Handley et al., 2013), we examined the role of cor-
tisol and IL-6 on these regional rCBF changes. Using StatisticalParametric Mapping (SPM, version 5, www.ﬁl.ion.ucl.ac.uk/spm), we
conducted paired samples t tests comparing haloperidol and
aripiprazole with placebo. We ﬁrst conﬁrmed that differences in hippo-
campal rCBF previously identiﬁed remained evident in the sub-group
with available cortisol and IL-6 data, and then conducted the analysis
again controlling for cortisol and IL-6 (separately) levels. A region of in-
terest (ROI) approach was employed, using a-priori anatomically de-
ﬁned masks of left and right hippocampus created using the Anatomy
toolbox extension (Eickhoff et al., 2005) in SPM5. Region of interest
(ROI) voxel-level statistics were accepted at p b 0.05 corrected for
family-wise error (FWE).
3. Results
3.1. Antipsychotic effect on cortisol levels
Prior to intervention, cortisol levels were not signiﬁcantly different
across intervention groups (F(2,32) = 1.305, not signiﬁcant). After
administering placebo, haloperidol and aripiprazole, the mean AUC
values for cortisol were 7.42 (SD: 0.28), 7.20 (SD: 0.25) and 7.47 (SD:
0.37) nmol min/l respectively. There was a signiﬁcant overall reduction
in cortisol levels (measured as AUC) following haloperidol (F(2,32) =
5.78, p = 0.007; evident in Fig. 1). Post hoc comparisons conﬁrmed
this was signiﬁcant in comparison to both placebo (p = 0.013; CI =
0.45, 0.406) and aripiprazole (p = 0.037; CI =−0.520,−0.014).
3.2. Antipsychotic effect on IL-6 levels
IL-6 data were acquired post intervention and available for a total of
12 subjects. After administering placebo, haloperidol and aripiprazole,
the mean IL-6 levels were 1.76 (SD: 1.07), 0.80 (SD: 0.33) and 1.21
(SD: 0.74) pg/ml, respectively. This indicated signiﬁcant lower IL-6
levels following haloperidol (F(2,22) = 4.19, p = 0.048), and post hoc
analysis revealed this was in comparison with placebo (p = 0.02;
CI = 0.14, 1.8) but not with aripiprazole (not signiﬁcant).
Since there was a signiﬁcant reduction in both cortisol and IL-6
levels following haloperidol compared with placebo, we explored
whether cortisol and IL-6 levels were correlated after these interven-
tions. There was no signiﬁcant correlation between cortisol and IL-6
after haloperidol (r = −0.459, not signiﬁcant) nor after placebo
(r =−0.303, not signiﬁcant).
3.3. Antipsychotic effect on resting cerebral blood ﬂow (rCBF)
The ﬁrst analysis conﬁrmed our previously published ﬁndings
(based on the larger dataset; (Handley et al., 2013)) that greater rCBF
was evident in the right (peak voxel: T = 6.47, p b 0.0001) and left
(peak voxel T = 5.17, p b 0.01) hippocampus following haloperidol
Fig. 2. Peak voxels within the hippocampus in which rCBF increased bilaterally following haloperidol (top), and on the left after aripiprazole (bottom), compared with placebo.
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pus after aripiprazole compared with placebo (Fig. 2) was also evident,
though the increase was only a trend in this sample (T = 4.07, p =
0.057).
We repeated this analysis to test whether these antipsychotic-
induced changes in hippocampal rCBF remained evident after
controlling for cortisol and IL-6 changes. We found that the differences
previously identiﬁed in hippocampal rCBF after both antipsychotics
were no longer signiﬁcant (haloperidol), or evident at trend level
(aripiprazole), suggesting cortisol and IL-6 largely accounted for
the hippocampal rCBF alteration evident following antipsychotic
administration.
4. Discussion
In this double-blind randomized study, we show for the ﬁrst time
that haloperidol, but not aripiprazole, lowers cortisol and IL-6 levels,
and increases hippocampal rCBF within hours of drug administration
and independently from the pathophysiology of psychosis. Our ﬁndings
also provide the ﬁrst novel, preliminary evidence that changes in
cortisol and IL-6 levels following haloperidol administration may ex-
plain the altered hippocampal rCBF observed after administration of
this antipsychotic drug.
Only one previous study has directly compared the effects of differ-
ent antipsychotics on cortisol levels in healthy individuals (Cohrs et al.,
2006). This group reported that cortisol levels remained unaffected by
haloperidol while a signiﬁcant reduction was evident following
olanzapine and quetiapine (SGAs) compared with placebo. In contrast
with these ﬁndings, we observed a signiﬁcant reduction in cortisol
levels after haloperidol, which may be due to our larger sample size
(N = 11 vs N = 17), allowing greater statistical power to identify
such change. It is noteworthy that Cohrs and colleagues reported an ab-
sence of haloperidol effect based on cortisol levels averaged across eight
(excluding baseline) time points, and their raw data indicate that at
14:00 h, a similar time to that driving our ﬁnding after this drug, cortisol
levels appeared lower than placebo. In line with our ﬁndings, another
study also reported signiﬁcant suppression of cortisol during laboratory
induced stress conditions following acute haloperidol administration
in healthy volunteers (Hennig et al., 1995). Furthermore, other
compounds characterised by high D2 receptor antagonism have
demonstrated similar suppressive effects on cortisol levels duringstress-induced conditions (Itoh et al., 2005); consistently, FGA treat-
ment has been associated with normalisation of previously raised corti-
sol levels also in patients with psychosis (Zhang et al., 2005).
The mechanisms through which haloperidol decreases cortisol levels
could be related to the strong antagonistic effect of this drug on dopamine
in the mesolimbic pathway, particularly in the striatum. Indeed, it has
been suggested that dopamine plays a stimulatory role in the control of
theHPAaxis,with several D2dopamine receptor agonists having been re-
ported to increase plasma corticosterone levels (Borowsky and Kuhn,
1992; Foreman et al., 1989); on the other hand, a reduction in dopaminer-
gic activity, as a result of high antagonism at the D2 receptors in the stri-
atum, could directly lead to lowered cortisol levels (Oswald et al., 2005;
Wand et al., 2007). This would suggest that the change in cortisol levels
we found following haloperidol administration results directly from the
pharmacodynamic effects of this antipsychotic.
In healthy volunteers, there are no studies exploring the effects of
FGAs on IL-6 in vivo, however one in vitro study investigated haloperi-
dol and chlorpromazine (both FGAs), quetiapine and clozapine (SGAs;
(Himmerich et al., 2011)) in healthy females and reported no effects
of any antipsychotic in toxic shock syndrome toxin TSST-1 -stimulated
blood cells. Numerous methodological differences are apparent be-
tween this study and our own, not least the in vitro vs in vivo nature
of investigation; moreover, it is possible that our larger sample and in-
clusion of a placebo condition allowed for the identiﬁcation of haloper-
idol effects. Interestingly, haloperidol has been previously associated
with reduced IL-6 levels in schizophrenia patients (Maes et al., 1995).
Elevated IL-6 levels have been reported to elicit changes in dopaminer-
gic function (Aguilar-Valles et al., 2012); conversely, our results also
demonstrate that, in healthy controls, manipulation of the dopaminer-
gic system (via haloperidol) can affect/reduce IL-6 levels. The immedia-
cy of these effects in our study provides further evidence that thesemay
be direct pharmacodynamic effects of haloperidol. This would, propose
that changes in these markers in schizophrenia patients are unlikely to
simply represent secondary drug effects resulting from reduced psycho-
social stress following symptom amelioration. Interestingly, we have
also recently shown that increased persistent levels of IL-6 in ﬁrst
episodepsychosis patients are associatedwithpoor treatment response,
supporting a role of the activation of the immune system for the
response to antipsychotic treatment (Mondelli et al., 2015).
The mechanisms through which haloperidol leads to a decrease in
IL-6 levels are still unclear. Indeed, in contrast to the well-recognized
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inﬂuence of dopamine on inﬂammatory responses remains more
contradictory, with differences across in vitro and in vivo studies. Also,
some authors suggest that the immunomodulatory effect of dopamine
might be mediated in a dose-dependent fashion by different types of
receptors (Basu and Dasgupta, 2000; Beck et al., 2004). Interestingly,
stimulation of D1 and D2 receptors has been described as leading to in-
hibition of NF-κB dependent transcription cascade, which has a key role
in regulating the inﬂammatory response. Alternatively, the HPA axis
could also partly be responsible for mediating the effects of haloperidol
on the immune system. It is well known that HPA axis can affect regula-
tion of immune system, and vice versa (Zunszain et al., 2011), partly
through shared down-stream molecular pathways, such as the NF-κB;
it is therefore possible that the effect of haloperidol on cortisol and
IL-6 levels depends, at least partly, on shared underlying molecular
pathways.
Our study is the ﬁrst one to speciﬁcally explore the effects of
aripiprazole on cortisol. In fact, all existing studies in patient samples
grouped individuals taking aripiprazole with those taking other SGAs
and did not explore the effects of this drug separately. Somehow unex-
pectedly, we did not ﬁnd any change in cortisol levels after aripiprazole.
Amongst other unique pharmacological properties that separate
aripiprazole from other SGAs, this drug has a lower afﬁnity for 5HT-2
than for D2 receptors (Mamo et al., 2007). It is interesting to note that
amisulpride, the only SGA that has a similarly lower afﬁnity for 5HT-2
than D2 receptors, has also been associated with an absence of effect
on cortisol in healthy individuals (Wetzel et al., 1994), suggesting that
the dopamine-serotonin afﬁnity proﬁle common to these drugs, and
not other SGAs, might be important in HPA axis regulation. Together
with the haloperidol effects evident in our study, this indicates that it
is not only the afﬁnity to dopamine receptors that is key in the regula-
tion of stress and pro-inﬂammatory markers, but also the function of
that drug on dopamine receptors (i.e. antagonistic vs partial agonism).
Similarly, no change in IL-6 was observed following aripiprazole.
Limited and mixed evidence for the effect of all SGAs on IL-6 makes it
challenging to understand whether aripiprazole effects on pro-
inﬂammatorymarkers are distinct from other SGAs, and if the lack of ef-
fect might be again related to its dopamine-serotonin afﬁnity proﬁle.
However, for cortisol at least this study demonstrates that aripiprazole
does not elicit changes comparable to those of other SGAs and future
investigation should separate this antipsychotic from the SGA group.
We have previously reported (Handley et al., 2013) increased rest-
ing blood ﬂow (rCBF) in the hippocampus following acute administra-
tion of haloperidol (bilaterally) and aripiprazole (left hippocampus),
comparedwith placebo. In the current studywe now ﬁnd that account-
ing for individual cortisol and IL-6 levels after each intervention
abolished this effect, suggesting that these biological markers may me-
diate, at least in part, hippocampal rCBF changes that follow the admin-
istration of these antipsychotics. Consistent with this notion, a number
of studies in healthy individuals have reported elevated cortisol levels
(artiﬁcially or stress induced) to be associated with lower hippocampal
restingmetabolism, lower rightmedial temporal lobe blood ﬂowduring
a declarative memory task and deactivation of hippocampus during a
stress task (de Leon et al., 1997; de Quervain et al., 2003; Pruessner
et al., 2008). These studies suggest that higher cortisol is associated
with decreased hippocampal function, and our ﬁnding that cortisol ex-
plains someof thehippocampal rCBF alterations observed after haloper-
idol is consistent with this hypothesis. Previous studies have reported
IL-6 as a potent vasoconstrictor and have shown that long-term treat-
ment with pro-inﬂammatory cytokine, such as IL-1β, decreases CBF
(Maher et al., 2003), while prolonged administration of the antagonist
IL-1 receptor antagonist increases CBF. This is again consistent with
our ﬁnding, and suggests that a reduction in IL-6 levels could be partly
responsible for the increase in hippocampal CBF following haloperidol.
Interestingly, we have also recently shown that both cortisol and IL-6
are associated with reduced hippocampal volume in ﬁrst-episodepsychosis patients (Mondelli et al., 2011, 2010b). On the basis of our
current ﬁndings, further studies would need to clarify if rCBF could be
considered a plausible mediator towards the previously observed
relationship between cortisol and IL-6 and structural hippocampal
change in psychotic patients.
The study has a number of strengths. Notably, all three interventions
were administered in a repeated measures design and cortisol, IL-6 and
hippocampal rCBF were acquired in the same individuals, limiting the
impact of intra-individual variability. To date, this is the largest and
ﬁrst study to acquire these measurements in healthy individuals
allowing for the direct pharmacodynamic drug effects to be interpreted
excluding the possible interaction of psychopathology.
Fewmain limitations of this study should be acknowledged. First,we
did notmeasure IL-6 prior to intervention, and used placebo as the base-
linemeasure for all individuals. However, the factorsmost likely to elicit
cortisol and IL-6 level variations across test days are diurnal rhythm and
dietary intake, and both these factors were controlled to ensure test
days were identical across interventions and between individuals.
Moreover, the baseline measures for cortisol were not signiﬁcantly
different, indicating that any factor that could potentially alter these
markers prior to the test day is unlikely to have had an impact on our
ﬁndings. Secondly, we chose to study the effects of these drugs on
healthy individuals, to examine their direct effects on stress markers
and brain perfusion. Therefore, by the very nature of our design,we can-
not establish whether in clinical samples any effect of antipsychotics on
stress markers and brain perfusion reﬂects a combined effect of under-
lying pathology and direct drug action. Third, we focussed our analysis
only on peripheral levels of IL-6, which may give us only limited infor-
mation about central inﬂammation; also, the analyses of other cytokines
could have provided a fuller picture of the effect of antipsychotic treat-
ment on the inﬂammatory response.
In conclusion, our ﬁnding that haloperidol but not aripiprazole re-
duces cortisol and IL-6 in healthy volunteers suggests that haloperidol
could regulate HPA axis and immune system through a direct pharma-
cological action via D2 receptor antagonism, and independently from
its effect on reducing psychosocial or symptom-induced stress.
Moreover, the absence of aripiprazole effects, particularly on cortisol
provides strong evidence that this antipsychotic is not directly compa-
rable to other SGAs, highlighting the importance of investigating drug
speciﬁc pharmacodynamic effects rather than groups of antipsychotic
drugs. Finally, our ﬁndings suggest a role of cortisol and IL-6 in mediat-
ing rCBF changes by antipsychotic treatment, further supporting stress
and inﬂammatory markers as viable possible targets for future antipsy-
chotic drug development.
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